Table 1.
Study | N | Intervention, dose | Comparator(s) | Duration | Diabetes or prediabetes | NASH or NAFLD | Country | NASH/NAFLD assessment in results |
---|---|---|---|---|---|---|---|---|
Aithal (36), | 74 | Pioglitazone, 30 mg/day | Placebo | 12 months | No | NASH | United Kingdom | Histology |
Anushiravani (37), | 60 a | Lifestyle + pioglitazone, 15 mg/day | Lifestyle + placebo | 3 months | No | NAFLD | Iran | Ultrasound |
Sanyal (38), | 163 a | Pioglitazone, 30 mg/day | Placebo | 24 months | No | NASH | America | Histology |
Belfort (11), | 47 a | Hypocaloric diet + pioglitazone, 45 mg/day | Hypocaloric diet + placebo | 6 months | Yes | NASH | America | Histology |
Cusi (12), | 101 | Pioglitazone, 45 mg/day | Placebo | 18 months | Yes | NASH | America | Histology |
Kamolvisit (39), | 98 | Pioglitazone, 45 mg/day | Placebo | 18 months | Yes | NAFLD | Thailand | Ultrasound |
Chehrehgosha (40), | 71 a | Pioglitazone, 30 mg/day | Placebo | 6 months | Yes | NAFLD | Iran | Ultrasound |
Represents patients in the trial arms of interest only.